Abstract
The standard of care regarding the duration of adjuvant tamoxifen treatment for patients with estrogen-receptor (ER)–positive breast cancer was
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
